OXiGENE, Inc. was a clinical-stage biopharmaceutical company that rebranded as in June 2016. The company specialized in developing Vascular Disrupting Agents (VDAs) designed to selectively dismantle blood vessels that sustain solid tumors and contribute to visual impairment. Corporate Evolution
On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN). Oxigene
Despite promising science, the company faced periodic financial restructurings, including a significant workforce reduction in 2011 to conserve resources for early-stage programs. OXiGENE, Inc
In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline Corporate Evolution On June 20, 2016, OXiGENE officially
OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer
Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye.
Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503